PZ0170
Torcetrapib
≥98% (HPLC)
别名:
(2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, CP-529,414, CP-529414
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C26H25F9N2O4
化学文摘社编号:
分子量:
600.47
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D >-70°
color
white
solubility
DMSO: >5 mg/mL
storage temp.
2-8°C
SMILES string
CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c3cc(ccc13)C(F)(F)F
InChI
1S/C26H25F9N2O4/c1-4-18-12-21(19-11-15(24(27,28)29)6-7-20(19)37(18)23(39)41-5-2)36(22(38)40-3)13-14-8-16(25(30,31)32)10-17(9-14)26(33,34)35/h6-11,18,21H,4-5,12-13H2,1-3H3/t18-,21+/m1/s1
InChI key
CMSGWTNRGKRWGS-NQIIRXRSSA-N
Application
Torcetrapib has been used as a reference standard in the medium chain-lipid based formulations.
Biochem/physiol Actions
Cholesteryl ester transfer protein (CETP) inhibitor.
Torcetrapib is a Cholesteryl ester transfer protein (CETP) inhibitor. CETP normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL levels (the "good" cholesterol-containing particle) and reduces LDL levels (the "bad" cholesterol). Unfortunately clinical trials were stopped because of excessive all cause mortality. Reasons are still being investigated, but may be related to some off target effects such as an increase in aldosterone secretion not found in some other CETP inhibitors.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
Philip J Barter et al.
Circulation, 124(5), 555-562 (2011-08-02)
High-density lipoproteins have antidiabetic properties in vitro. Furthermore, elevated high-density lipoprotein levels accompanying a genetic deficiency of cholesteryl ester transfer protein are associated with decreased levels of plasma glucose. We now investigate effects on glucose homeostasis of inhibiting cholesteryl ester
Stephen J Nicholls
Current cardiology reports, 14(3), 245-250 (2012-03-01)
Considerable attention focuses on the ability to develop therapeutic agents that elevate levels of high-density lipoprotein cholesterol (HDL-C). Cholesteryl ester transfer protein (CETP) inhibitors have been developed on the basis of their ability to raise HDL-C to a greater extent
Shenping Liu et al.
The Journal of biological chemistry, 287(44), 37321-37329 (2012-09-11)
Human plasma cholesteryl ester transfer protein (CETP) transports cholesteryl ester from the antiatherogenic high-density lipoproteins (HDL) to the proatherogenic low-density and very low-density lipoproteins (LDL and VLDL). Inhibition of CETP has been shown to raise human plasma HDL cholesterol (HDL-C)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| PZ0170-25MG | 04061833058039 |
| PZ0170-5MG | 04061833058046 |